A Prospective, Multicenter Phase II Study of the Efficacy and Feasibility of 15-minute Panitumumab Infusion Plus Irinotecan for Oxaliplatin- and Irinotecan-refractory, KRAS Wild-type Metastatic Colorectal Cancer (Short Infusion of Panitumumab Trial)

Kasuga, Akiyoshi; Hamaguchi, Tetsuya; Yoshimura, Kenichi; Takahashi, Naoki; Honma, Yoshitaka; Iwasa, Satoru; Takashima, Atsuo; Kato, Ken; Yamada, Yasuhide; Onodera, Hisashi; Takeshita, Shigeyuki; Yasui, Hisateru; Sakai, Gen; Akatsuka, Sotaro; Ogawa, Kazuhiko; Horita, Yuki; Nagai, Yushi; Shimada, Yasuhiro

doi:10.1016/j.clcc.2017.10.004

Cited by 2 publications

(2 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The remaining 34 patients received a total of 187 doses in 15 min. No infusion-related reactions were noted in the entire study, resulting in the investigators' conclusion that the short-infusion regimen was well tolerated and did not compromise safety or efficacy (48).…”

Section: Resultsmentioning

confidence: 91%

Systematic Review on Infusion Reactions to and Infusion Rate of Monoclonal Antibodies Used in Cancer Treatment

et al. 2020

View full text Add to dashboard Cite

Background: Patients with cancer who are treated with monoclonal antibodies are at risk for developing infusion reactions. However, for some monoclonal antibodies, the incidence of infusion reactions is low or can be lowered by the use of adequate premedication schedules. It is often feasible to increase the infusion rate/lower the post-administration observation time. This review gives an overview of infusion reactions and the possibility of accelerating infusion rates. Materials and Methods: Data on infusion reactions and infusion rates for all monoclonal antibodies that are licensed in the European Union for treatment of solid tumors or hematological malignancies, found by a literature search, were included in this review. Results: For 11 out of the 21 monoclonal antibodies data exceeding the registration text were found and described. Faster infusion schedules are possible for bevacizumab, ipilimumab, nivolumab, panitimumab, and rituximab. Conclusion: We propose optimal infusion schedules for each drug.

show abstract

Section: Resultsmentioning

confidence: 91%

Systematic Review on Infusion Reactions to and Infusion Rate of Monoclonal Antibodies Used in Cancer Treatment

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Targeted therapy has been standardized in front-line therapies for mCRC, but explicit recommendations for third-or later-line are still lacking. As far as it is concerned, several studies reported the efficacy and safety of targeted treatment alone or combined chemotherapy (16,(21)(22)(23)(24)(25)(26)(27)(28). This study aimed to conduct a meta-analysis through a synthesis of the evidence to generate a comprehensive assessment of efficacy and safety of third-line or later-line targeted treatment for patients with mCRC and subsequently to provide evidence and clues for clinical research and practice.…”

Section: Introductionmentioning

confidence: 99%

Efficacy and safety of third-line or later-line targeted treatment for patients with metastatic colorectal cancer: a meta-analysis

Xue

Ding

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

Targeted therapy has been standardized in front-line therapies for metastatic colorectal cancer (mCRC), while explicit recommendations for third- or later-line are still lacking. This study evaluated the efficacy and safety of combining targeted therapy with chemotherapy in the third- or later-line treatment for mCRC via meta-analysis, providing evidence-based guidance for clinical or research practice. Comprehensive retrieval of related studies was conducted according to the PRISMA guideline. Studies were stratified with patient characteristics and pharmacological classification of the drugs. For the data available for quantitative analysis, pooled overall response rate, disease control rate, hazard ratios (HRs) for overall survival (OS) and progression-free survival (PFS), and adverse events rate with respective 95% confidence intervals (CIs) were calculated. A total of 22 studies (1,866 patients) were included in this meta-analysis. Data from 17 studies (1,769 patients) involving targets of epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) were extracted for meta-analyses. The overall response rates for monotherapy and combined therapy were 4% (95% CI: 3%, 5%) and 20% (95% CI: 11%, 29%). The pooled HRs (combined therapy vs. mono) for OS and PFS were 0.72 (95% CI: 0.53, 0.99) and 0.34 (95% CI: 0.26, 0.45). Another five studies were included in narrative depiction, involving targets of BRAF, HER-2, ROS1, and NTRK. The findings of this meta-analysis indicate that VEGF and EGFR inhibitors manifest promising clinical response rates and prolonged survival in the treatment of mCRC with acceptable adverse events.

show abstract

A Prospective, Multicenter Phase II Study of the Efficacy and Feasibility of 15-minute Panitumumab Infusion Plus Irinotecan for Oxaliplatin- and Irinotecan-refractory, KRAS Wild-type Metastatic Colorectal Cancer (Short Infusion of Panitumumab Trial)

Cited by 2 publications

References 16 publications

Systematic Review on Infusion Reactions to and Infusion Rate of Monoclonal Antibodies Used in Cancer Treatment

Systematic Review on Infusion Reactions to and Infusion Rate of Monoclonal Antibodies Used in Cancer Treatment

Efficacy and safety of third-line or later-line targeted treatment for patients with metastatic colorectal cancer: a meta-analysis

Contact Info

Product

Resources

About